Wan Zamaniah Wan Ishak
University Malaya Medical Centre(MY)University of Malaya(MY)
Publications by Year
Research Areas
Head and Neck Cancer Studies, Cancer Immunotherapy and Biomarkers, Advanced Radiotherapy Techniques, Lung Cancer Treatments and Mutations, Gastric Cancer Management and Outcomes
Most-Cited Works
- → Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study(2019)3,087 cited
- → Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study(2022)450 cited
- → KEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)(2018)134 cited
- → Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).(2019)131 cited
- → Strain‐specific probiotic (microbial cell preparation) and omega‐3 fatty acid in modulating quality of life and inflammatory markers in colorectal cancer patients: a randomized controlled trial(2017)96 cited
- → Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE‐063): A randomized, open‐label, phase 3 trial in Asian patients(2021)68 cited
- → Understanding the Financial Needs Following Diagnosis of Breast Cancer in a Setting with Universal Health Coverage(2020)45 cited
- → Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048(2022)39 cited
- → In vivo skin dose measurement using MOSkin detectors in tangential breast radiotherapy(2016)25 cited
- → Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: 5-year follow-up from the randomized phase III KEYNOTE-048 study(2025)24 cited